
Keywords: AA; arachidonic acid; NSAID; non-steroidal anti-inflammatory drug; FAP; familial adenomatous polyposis; TA; tolfenamic acid; SS; sulindac sulfide; EGR-1; early growth response-1; NAG-1; NSAID-activated gene-1; EMT; epithelial-mesenchymal transition; bZIP;